The current financial score of AnaptysBio Inc is 8.14. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 25.56M, representing a year-over-year decrease of 7.98%, while its net profit experienced a year-over-year decrease of 34.47%.
The current valuation score of AnaptysBio Inc is 9.12. Its current P/E ratio is -49.78, which is -95.67% below the recent high of -2.16 and -206.06% above the recent low of -152.35.
The current earnings forecast score of AnaptysBio Inc is 8.73. The average price target is 89.88, with a high of 140.00 and a low of 75.00.
The current price momentum score of AnaptysBio Inc is 3.54. Currently, the stock price is trading between the resistance level at 56.57 and the support level at 47.27, making it suitable for range-bound swing trading.
The current institutional shareholding score of AnaptysBio Inc is 10.00. The latest institutional shareholding proportion is 101.42%, representing a quarter-over-quarter decrease of 37.03%.
The current risk assessment score of AnaptysBio Inc is 6.13. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.